Moderna Enters Material Definitive Agreement

TL;DR

Moderna just signed a big deal, creating a new financial obligation. Details to follow.

AI Summary

On November 19, 2025, Moderna, Inc. entered into a material definitive agreement, creating a direct financial obligation. The filing details this agreement and related financial obligations under an off-balance sheet arrangement. Specific details of the agreement, including the nature of the obligation and any associated dollar amounts or parties, are not fully disclosed in the provided text.

Why It Matters

This filing indicates a new financial commitment or obligation for Moderna, which could impact its financial structure and future operations.

Risk Assessment

Risk Level: medium — The creation of a new financial obligation, without immediate disclosure of its terms, introduces uncertainty regarding Moderna's financial commitments.

Key Players & Entities

• Moderna, Inc. (company) — Registrant
• November 19, 2025 (date) — Date of earliest event reported
• 325 Binney Street (location) — Principal executive offices address
• Cambridge, MA (location) — Principal executive offices city and state
• 02142 (location) — Principal executive offices zip code

FAQ

From the Filing

0001628280-25-053816.txt : 20251124 0001628280-25-053816.hdr.sgml : 20251124 20251124162939 ACCESSION NUMBER: 0001628280-25-053816 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20251119 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251124 DATE AS OF CHANGE: 20251124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 251513456 BUSINESS ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 8-K 1 mrna-20251119.htm 8-K mrna-20251119 0001682852 false 0001682852 2025-11-19 2025-11-19   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware   001-38753   81-3467528  (State or other jurisdiction of incorporation)    (Commission File Number)    (IRS Employer Identification No.)   325 Binney Street Cambridge , MA   02142 (Address of principal executive offices)   (Zip code) Registrant’s telephone number, including area code: ( 617 )  714-6500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company       ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐ Item 1.01.    Entry into a Material Definitive Agreement. On November 19, 2025, Moderna, Inc. (the “Company”) entered into a Credit and Guaranty Agreement (the “Credit Agreement”), among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent. The Credit Agreement provides for a $1,500,000,000 credit facility of which $600,000,000 will be funded as an initial term loan a